Test Price
1,500 AED✅ Home Collection Available
C1 Esterase Inhibitor Functional Test in UAE | 1500 AED | 2026 DHA Guidelines
تحليل وظائف مثبط إستراز C1 في الإمارات | 1500 درهم | معتمد من هيئة الصحة بدبي
Executive Summary — الملخص التنفيذي
Clinical Precision: The C1 Esterase Inhibitor Functional Test delivers 99.9% Diagnostic Sensitivity for Hereditary Angioedema (HAE) Type I and Type II differentiation, processed exclusively through ISO 9001:2015 accredited laboratory protocols (Cert: INT/EGQ/2509DA/3139). This quantitative Enzyme Immunoassay (ELISA) measures the functional activity — not merely the antigenic presence — of C1-INH protein, making it the gold standard for confirming complement system disorders where antigenic assays alone may miss Type II HAE (normal protein levels with dysfunctional C1-INH).
الفحص التشخيصي المعتمد: اختبار وظائف مثبط C1 إستراز هو تحليل تشخيصي متخصص ومعتمد من هيئة الصحة بدبي لتقييم النشاط الوظيفي لبروتين مثبط C1 في النظام المتمم. يُستخدم هذا الفحص المخبري بدقة تشخيصية تبلغ 99.9% لتحديد الوذمة الوعائية الوراثية بنوعيها الأول والثاني، ويُجرى وفق معايير الآيزو 9001:2015.
Hospital-Grade Home Collection via ISO-Certified Cold-Chain Phlebotomy. VIP Mobile Phlebotomy available 8 AM – 11 PM across all Emirates. Serum separation within 1 hour, immediate flash-freezing, and frozen transport maintained at -20°C throughout.
Complimentary Telephonic Post-Test Clinical Guidance for result interpretation. Direct Billing Insurance Verification via WhatsApp: +971 54 548 8731. Same-day pre-authorization for major UAE insurers including Daman, AXA, MetLife, and Neuron.
Clinical Overview: Understanding the C1 Esterase Inhibitor Functional Test
The C1 Esterase Inhibitor (C1-INH) Functional Test quantifies the enzymatic inhibitory activity of C1-INH protein in serum — a critical regulator of the classical complement pathway, kallikrein-kinin system, and coagulation cascade. Deficient or dysfunctional C1-INH leads to uncontrolled bradykinin production, manifesting clinically as Hereditary Angioedema (HAE) with recurrent, potentially life-threatening submucosal and subcutaneous swelling. This test is indispensable for differentiating HAE from histaminergic angioedema and guiding targeted prophylaxis with C1-INH concentrates, icatibant, or ecallantide.
يقيس هذا الاختبار النشاط الوظيفي لبروتين مثبط C1 إستراز في مصل الدم، وهو فحص أساسي لتشخيص الوذمة الوعائية الوراثية وتحديد نوعها بدقة.
Diagnostic Comparison: Our Functional ELISA vs. Antigenic Assay
| Parameter | Our C1-INH Functional Test (ELISA) | C1-INH Antigenic Test (Alternative) |
|---|---|---|
| What It Measures | Functional inhibitory activity — how well C1-INH actually works | Quantitative protein concentration only |
| HAE Type II Detection | ✓ Detects Type II — low function despite normal protein levels | ✗ Misses Type II — protein levels appear normal |
| Methodology | Enzyme Immunoassay (ELISA) — Quantitative Functional | Nephelometry / Radial Immunodiffusion |
| Sensitivity for HAE | 99.9% — Both Type I & Type II | ~85% — Type I only; Type II missed entirely |
| Turnaround Time | Sample by 7th of month; Report in 2–3 weeks (batch-processed) | 3–7 days (routine lab) |
| Clinical Utility | Definitive diagnosis — guides life-saving therapy selection | Screening only — requires functional confirmation |
Physician Insight & Clinical Safety Protocol
A Note from Dr. PRABHAKAR REDDY, DHA License: 61713011:
"The C1 Esterase Inhibitor Functional Test is not a routine screening — it is a definitive confirmatory assay reserved for patients with a high clinical index of suspicion for Hereditary Angioedema. I have seen families where generations suffered from unexplained abdominal attacks and orofacial swelling, only to be diagnosed decades later through this very test. Please understand that a normal result does not exclude all complement disorders; clinical correlation with complement C4 levels, C1q binding assays, and genetic testing for SERPING1 mutations is essential. This test requires meticulous pre-analytical handling — even a single freeze-thaw cycle can denature the labile C1-INH protein and yield a falsely low result."
⚕️ Critical Medication Advisory
Do not discontinue any prescribed medication without consulting your treating physician. Patients on danazol, stanozolol, tranexamic acid, or C1-INH replacement therapy (Berinert®, Cinryze®, Haegarda®) must inform their ordering physician, as these agents directly modulate C1-INH levels and functional activity. Abrupt cessation of prophylactic androgens may precipitate an acute HAE attack, including life-threatening laryngeal edema.
⚠️ Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do NOT Collect If:
- Patient received C1-INH concentrate infusion within the past 72 hours (falsely normalizes functional activity).
- Serum cannot be separated and frozen within 1 hour of venipuncture — delayed processing degrades C1-INH.
- SST gel barrier tubes used — gel interferes with the ELISA reaction; only Red Top (No Additive) tubes are acceptable.
- Sample previously thawed — even one freeze-thaw cycle invalidates results. DO NOT THAW.
- Patient is experiencing an acute phase response (CRP >50 mg/L) — may transiently elevate C1-INH as an acute phase reactant.
- Form 35 (Test Send Out Consent Form) not duly filled and signed.
🚨 Emergency Red Flags — Seek Immediate ER Care If:
- Swelling of the tongue, throat, or larynx with voice changes or stridor — impending airway obstruction.
- Severe abdominal pain with vomiting and guarding — may indicate intestinal angioedema mimicking acute abdomen.
- Facial or periorbital swelling progressing rapidly within minutes to hours.
- Any swelling that does not respond to antihistamines, corticosteroids, or epinephrine — hallmark of bradykinin-mediated HAE.
- Family history of sudden death from "choking" or unexplained laryngeal edema.
Pre-Test Requirements & Specimen Handling Protocol
Referring Specialists for This Test
Clinical Immunologist
Primary specialist for complement system disorders, HAE diagnosis, and long-term immunomodulatory management.
General Physician
First-line recognition of recurrent angioedema patterns; initiates diagnostic workup and coordinates specialist referral.
Anti-Aging & Preventive Medicine Specialist
Identifies subclinical complement dysregulation in comprehensive wellness and longevity panels for at-risk families.
Frequently Asked Questions — C1 Esterase Inhibitor Functional Test
1. Why is the functional C1-INH test preferred over the antigenic C1-INH test for diagnosing Hereditary Angioedema?
The functional C1-INH assay measures actual inhibitory enzyme activity, making it the only test capable of detecting Type II HAE where C1-INH protein levels are normal but the protein is dysfunctional. Approximately 15% of HAE patients have Type II disease with normal or even elevated C1-INH antigen levels — these cases are completely missed by antigenic assays alone. The functional ELISA quantifies the residual esterase inhibitory capacity, providing a comprehensive assessment that distinguishes healthy individuals from both Type I (low protein, low function) and Type II (normal protein, low function) HAE patients. This diagnostic precision directly impacts treatment selection, as icatibant and ecallantide are effective regardless of HAE type, while C1-INH concentrate dosing may differ.
2. What precautions are essential for accurate C1-INH functional test results?
Meticulous pre-analytical handling is non-negotiable: serum must be separated within 60 minutes of venipuncture, immediately frozen at -20°C, and transported on dry ice without any thawing. C1-INH is a thermolabile protein susceptible to in-vitro degradation; even a single freeze-thaw cycle reduces functional activity by 30–50%, generating falsely low results that may lead to an erroneous HAE diagnosis. Additionally, blood must be collected in plain Red Top tubes without gel separators, as SST gel barriers adsorb complement proteins and interfere with the ELISA detection system. Patients receiving C1-INH replacement therapy should ideally pause infusions 72 hours before testing (under physician supervision), and acute illness with elevated CRP should be resolved prior to sample collection, as C1-INH behaves as an acute-phase reactant.
3. How should patients interpret a low C1-INH functional result, and what are the next clinical steps?
A low C1-INH functional result (<40% of normal reference range) is highly suggestive of C1-INH deficiency and warrants immediate confirmatory testing with complement C4 levels and SERPING1 genetic analysis. C4 is a natural substrate consumed during unchecked classical pathway activation; a concomitantly low C4 level (below 30% of normal) strongly supports the diagnosis of HAE and helps differentiate C1-INH deficiency from acquired angioedema (where C1q levels are also reduced). All first-degree relatives of confirmed HAE patients should undergo cascading family screening. In the UAE, DHA guidelines recommend referral to a Clinical Immunologist for comprehensive management, including a written emergency action plan for acute attacks, home-based rescue medication (icatibant or C1-INH concentrate), and documentation of HAE diagnosis for emergency department visits.
استشارة طبيب المناعة السريرية ضرورية بعد تلقي نتيجة منخفضة لوظائف مثبط C1 إستراز لتأكيد التشخيص وبدء خطة العلاج الوقائي والطارئ.
UAE Regulatory Compliance & Legal Framework
Federal Decree-Law No. 41 of 2024 (Article 87): This laboratory strictly adheres to all provisions governing diagnostic testing, patient consent, and data confidentiality as mandated by the UAE Ministry of Health and Prevention (MOHAP). All test results are processed and stored in full compliance with the Federal Decree-Law on Health Data Protection.
CDS Law 2026 — Minors: For patients under 18 years of age, written informed consent from a legal guardian is mandatory prior to sample collection. Genetic counselling is recommended for paediatric HAE testing, as childhood-onset symptoms may present as early as 2–3 years of age.
UAE PDPL (Personal Data Protection Law): All patient identifiers, genetic information, and test results are encrypted and stored on secure, UAE-sovereign servers in compliance with the UAE Personal Data Protection Law. Data is never shared with third parties without explicit patient authorization.
ISO 9001:2015 Certification: Certificate No. INT/EGQ/2509DA/3139 — Validated Quality Management System ensuring consistent, reproducible, and internationally benchmarked diagnostic accuracy.
ICD-10-CM 2026 Codes: D84.1 (Defects in the Complement System — C1 Esterase Inhibitor Deficiency), T78.3XXA (Angioneurotic Edema, Initial Encounter), Z15.89 (Genetic Susceptibility to Other Disease — SERPING1 Mutation Carrier Screening).
LOINC Code: LOINC 4477-9 — C1 Esterase Inhibitor Functional Activity [Units/Volume] in Serum. Methodology: Enzyme Immunoassay (ELISA), Quantitative Functional Assay.
Schedule Your C1 Esterase Inhibitor Functional Test — 1500 AED
VIP Home Collection | ISO-Certified Cold Chain | DHA-Licensed Facility 9834453 | Post- Clinical Guidance Included
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians